RAPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. RAPT is trading at ~$57.68 versus a definitive $58.00 all-cash takeout by GSK, leaving ~0.6% gross upside with real downside if the deal is delayed or breaks. For an impatient trader unwilling to wait, the risk/reward is unattractive at this price (classic merger-arb compression).
Price trend is strongly bullish but stretched: SMA_5 > SMA_20 > SMA_200 confirms an uptrend, however RSI_6 at 89 signals extreme overbought conditions and limited near-term upside. MACD histogram is positive (1.474) but positively contracting, consistent with momentum fading after a sharp run-up. Price is also pressing near R1 (58.178) with the deal price at $58 acting as a hard ceiling; upside to R2 (~64.245) is unlikely while the cash-acquisition cap exists. Near-term pattern stats also skew to a small next-day pullback (60% chance to -1.25%).
Definitive catalyst: GSK agreement to acquire RAPT for $58/share in cash, which supports price stability near the deal level and provides a clear near-term valuation anchor if the transaction closes as expected.
Key risk is deal risk (regulatory/timing/financing/closing conditions). With the stock already near $58, the downside on any negative headline is meaningfully larger than the remaining upside. News flow is dominated by shareholder-law-firm “investigations” related to the sale process (often noise, but can add uncertainty). Hedge funds are reported net sellers (selling amount increased ~392% last quarter), consistent with merger-arb participants exiting as spread collapses.
Latest provided quarter: 2025/Q3. Revenue remained at 0 (no YoY growth), while losses worsened: net income -$17.58M (down ~4.62% YoY) and EPS -$0.65 (down ~82.85% YoY). Overall, fundamentals remain typical for a pre-revenue biotech (cash burn / widening per-share loss), and the current price action is primarily deal-driven rather than driven by improving operating performance.
Analyst sentiment shifted sharply negative (mechanically) after the GSK deal: multiple downgrades to Hold/Equal Weight/Market Perform with price targets set to $58 (Barclays, Leerink, Wells Fargo, TD Cowen, LifeSci, H.C. Wainwright). Prior to the deal, ratings and targets were more optimistic (e.g., Piper Sandler Overweight $95; earlier Buy/Overweight calls), but the acquisition effectively caps upside at $58. Wall Street pros view now: Pros—high visibility to $58 cash if deal closes; Cons—minimal remaining upside spread and asymmetric downside if the deal breaks. Politician/congress activity: no recent congress trading data available; insider trend noted as neutral.
